Literature DB >> 1248064

Vascular responses to arachidonic acid in the perfused canine lung.

T C Wicks, J C Rose, M Johnson, P W Ramwell, P A Kot.   

Abstract

We compared the effects of arachidonic acid (AA), the bisenoic prostaglandin precursor, with those of prostaglandin F2a (PGF2a) and norepinephrine (NE) on pulmonary vascular resistance in the isolated (in situ), perfused canine lung lobe. The isolated lobe was perfused with autologous blood or an artificial perfusate under conditions of constant flow. Lobar artery and venous pressures were constantly monitored after bolus injections of AA, PGF2a, and NE into the inflow cannula. AA (100 mug/kg produced a significant increase in the pressure gradient (93.3 +/- 8.4%, SE) in the lobe. Similarly, PGF2a (1 mug/kg) significantly increased the pressure gradient (41.2 +/- 6.5%), as did NE (1 mug/kg, 41.6 +/- 3.2%). Aspirin (25 mg/kg) completely blocked the pulmonary vascular effect of AA, but did not affect the response to PGF2a, Linoleic acid, a control fatty acid, did not produce pulmonary vasoconstriction. The pressor effect of AA was not blocked by pretreatment with phentolamine, propranolol, cyproheptadine, or atropine. The use of an artificial perfusate free of cellular elements did not prevent the vasoconstrictor action of AA. The times to onset of action of the three agents were similar, and short. These results suggest that AA is converted into vasoactive intermediates or a prostaglandin, and the vasoactive intermediates or the prostaglandin act directly on precapillary pulmonary vascular smooth muscle rather than through platelet, plasma, adrenergic, or cholinergic mechanisms.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1248064     DOI: 10.1161/01.res.38.3.167

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  13 in total

Review 1.  Introduction: thromboxane in biological systems and the possible impact of its inhibition.

Authors:  M Verstraete
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

2.  [Increase of pulmonary vascular resistance and permeability due to the metabolism of free arachidonic acid (author's transl)].

Authors:  W Seeger; H Wolf; G Stähler; H Neuhof; L Róka
Journal:  Klin Wochenschr       Date:  1981-05-04

3.  Biotransformation of arachidonic acid in the circulation of the dog [proceedings].

Authors:  G J Dusting; S Moncada; K M Mullane; J R Vane
Journal:  Br J Pharmacol       Date:  1978-06       Impact factor: 8.739

4.  The effects of arachidonic acid and non-steroidal anti-inflammatory drugs on intrapulmonary airways of the guinea-pig.

Authors:  T P Clay; D C Fenske
Journal:  Br J Pharmacol       Date:  1984-02       Impact factor: 8.739

5.  Pulmonary vascular effects of fat emulsion infusion in unanesthetized sheep. Prevention by indomethacin.

Authors:  C R McKeen; K L Brigham; R E Bowers; T R Harris
Journal:  J Clin Invest       Date:  1978-05       Impact factor: 14.808

6.  Vasoconstrictor response to arachidonic acid in the isolated hind limb of the dog.

Authors:  T M Fitzpatrick; M Johnson; P A Kot; P W Ramwell; J C Rose
Journal:  Br J Pharmacol       Date:  1977-02       Impact factor: 8.739

7.  Circulatory effects of prostaglandin endoperoxide analogues studied in the dog during left ventricular bypass.

Authors:  I Alter; P A Kot; P W Ramwell; J C Rose; M R Shnider
Journal:  Br J Pharmacol       Date:  1977-11       Impact factor: 8.739

Review 8.  Lung Circulation.

Authors:  Karthik Suresh; Larissa A Shimoda
Journal:  Compr Physiol       Date:  2016-03-15       Impact factor: 9.090

9.  Coronary vasoconstrictor and vasodilator actions of arachidonic acid in the isolated perfused heart of the rat.

Authors:  S E Belo; J Talesnik
Journal:  Br J Pharmacol       Date:  1982-02       Impact factor: 8.739

10.  Effect of verapamil on the pulmonary vasoconstrictor action of prostaglandin F2 alpha and a synthetic PGH2 analogue.

Authors:  A D Angerio; T M Fitzpatrick; P A Kot; P W Ramwell; J C Rose
Journal:  Br J Pharmacol       Date:  1981-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.